Evidence map›Paper›PMID 37439806›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2024

Zerumbone-incorporated liquid crystalline nanoparticles inhibit proliferation and migration of non-small-cell lung cancer in vitro.

Bikash Manandhar, Keshav Raj Paudel, Dvya Delilaa Clarence, Gabriele De Rubis, Thiagarajan Madheswaran, Jithendra Panneerselvam, Flavia C Zacconi, Kylie A Williams, Lisa G Pont, Majid Ebrahimi Warkiani and 7 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 5 countries.

Bikash Manandhar *Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW, 2007, Australia.
Keshav Raj Paudel *Centre for Inflammation, Centenary Institute and University of Technology Sydney, Faculty of Science, School of Life Sciences, Sydney, NSW 2050, Australia.
Dvya Delilaa ClarenceSchool of Postgraduate Studies, International Medical University (IMU), 57000, Kuala Lumpur, Malaysia.
Gabriele De RubisDiscipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW, 2007, Australia.
Thiagarajan MadheswaranDepartment of Pharmaceutical Technology, School of Pharmacy, International Medical University, 57000, Kuala Lumpur, Malaysia.
Jithendra PanneerselvamDepartment of Pharmaceutical Technology, School of Pharmacy, International Medical University, 57000, Kuala Lumpur, Malaysia.
Flavia C ZacconiDepartamento de Química Orgánica, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Av. Vicuña Mackenna 4860, 7820436, Macul, Santiago, Chile.
Kylie A WilliamsDiscipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW, 2007, Australia.
Lisa G PontDiscipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW, 2007, Australia.
Majid Ebrahimi WarkianiSchool of Biomedical Engineering, University of Technology Sydney, Sydney, New South Wales, Australia.
Ronan MacLoughlinResearch and Development, Aerogen Limited, IDA Business Park, Galway, Connacht, H91 HE94, Ireland.
Brian Gregory OliverWoolcock Institute of Medical Research, Macquarie University, Sydney, NSW, 2137, Australia.
Gaurav GuptaSchool of Pharmacy, Suresh Gyan Vihar University, Jaipur, Rajasthan, India.
Sachin Kumar SinghAustralian Research Centre in Complementary and Integrative Medicine, Faculty of Health, University of Technology Sydney, Sydney, NSW, 2007, Australia.
Dinesh Kumar ChellappanDepartment of Life Sciences, School of Pharmacy, International Medical University, 57000, Kuala Lumpur, Malaysia. dinesh_kumar@imu.edu.my.
Philip M HansbroCentre for Inflammation, Centenary Institute and University of Technology Sydney, Faculty of Science, School of Life Sciences, Sydney, NSW 2050, Australia. philip.hansbro@uts.edu.au.
Kamal DuaDiscipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW, 2007, Australia. kamal.dua@uts.edu.au.
University of Technology Sydney · AUInternational Medical University · MYLovely Professional University · INMacquarie University · AUPontificia Universidad Católica de Chile · CLRoyal College of Surgeons in Ireland · IESaveetha University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung cancer is the second most prevalent type of cancer and is responsible for the highest number of cancer-related deaths worldwide. Non-small-cell lung cancer (NSCLC) makes up the majority of lung cancer cases. Zerumbone (ZER) is natural compound commonly found in the roots of Zingiber zerumbet which has recently demonstrated anti-cancer activity in both in vitro and in vivo studies. Despite their medical benefits, ZER has low aqueous solubility, poor GI absorption and oral bioavailability that hinders its effectiveness. Liquid crystalline nanoparticles (LCNs) are novel drug delivery carrier that have tuneable characteristics to enhance and ease the delivery of bioactive compounds. This study aimed to formulate ZER-loaded LCNs and investigate their effectiveness against NSCLC in vitro using A549 lung cancer cells. ZER-LCNs, prepared in the study, inhibited the proliferation and migration of A549 cells. These inhibitory effects were superior to the effects of ZER alone at a concentration 10 times lower than that of free ZER, demonstrating a potent anti-cancer activity of ZER-LCNs. The underlying mechanisms of the anti-cancer effects by ZER-LCNs were associated with the transcriptional regulation of tumor suppressor genes P53 and PTEN, and metastasis-associated gene KRT18. The protein array data showed downregulation of several proliferation associated proteins such as AXL, HER1, PGRN, and BIRC5 and metastasis-associated proteins such as DKK1, CAPG, CTSS, CTSB, CTSD, and PLAU. This study provides evidence of potential for increasing the potency and effectiveness of ZER with LCN formulation and developing ZER-LCNs as a treatment strategy for mitigation and treatment of NSCLC.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsNanoparticlesSesquiterpenesApoptosisCell Line, TumorCell ProliferationHumansSesquiterpeneszerumboneA549 lung cancer cellsCell migrationCell proliferationLiquid crystalline nanoparticlesNon-small-cell lung cancerZerumbone

Identifiers

PMID37439806
PMCPMC10771618
OpenAlexW4384126483

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.